Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102704 | 0.89 | HSD17B1 (0.55) | HSD17B1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL4095452 | 0.86 | HSD17B1 (0.71) | HSD17B1KMT2AMEN1 | |
| SCHEMBL13774778 | 0.83 | HSD17B1 (0.73) | HSD17B1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4095854 | 0.81 | HSD17B1 (1.00) | HSD17B1ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL4101697 | 0.75 | HSD17B1 (0.57) | HSD17B1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4104783 | 0.71 | HSD17B1 (0.80) | HSD17B1KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL4100679 | 0.69 | HSD17B1 (0.56) | HSD17B1 | |
| SCHEMBL4085279 | 0.65 | HSD17B1 (0.45) | HSD17B1KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL4085986 | 0.65 | HSD17B1 (0.53) | HSD17B1 | |
| SCHEMBL4093483 | 0.64 | HSD17B1 (0.50) | HSD17B1KMT2AMEN1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885KMT2A 2145/4885MEN1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.